Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $17.3 million.

  • Amicus Therapeutics' Income from Continuing Operations rose 35718.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 8656.87%. This contributed to the annual value of -$56.1 million for FY2024, which is 6298.69% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Income from Continuing Operations is $17.3 million, which was up 35718.53% from -$24.4 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Income from Continuing Operations peaked at $17.3 million during Q3 2025, and registered a low of -$85.3 million during Q1 2022.
  • Its 5-year average for Income from Continuing Operations is -$38.1 million, with a median of -$43.2 million in 2023.
  • Over the last 5 years, Amicus Therapeutics' Income from Continuing Operations had its largest YoY gain of 35718.53% in 2025, and its largest YoY loss of 5557.11% in 2025.
  • Amicus Therapeutics' Income from Continuing Operations (Quarter) stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then surged by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then rose by 17.42% to $17.3 million in 2025.
  • Its Income from Continuing Operations was $17.3 million in Q3 2025, compared to -$24.4 million in Q2 2025 and -$21.7 million in Q1 2025.